PubMed Health⌕ Search

Biomedical subjects

P Pfitzner

Publications and source records attributed to P Pfitzner.

30 records · Page 2Linked to original sources
PubMed1995

Infections after cardioverter-defibrillator implantation: observations in 335 patients over 10 years.

OBJECTIVE: To determine the incidence of infection after implantation of a cardioverter-defibrillator and the management of this complication. SUBJECTS: 335 consecutive patients who had a cardioverter-defibrillator implanted between January 1984 and December 1993. MAIN OUTCOME MEASURES: Incidence of infection within the first month after implantation (early infection) and after the first month (late infection). RESULTS: Infections associated with cardioverter-defibrillator devices occurred in 13 patients (3.9%) during a mean follow up of 22 (11) months. All patients had general signs of inflammation, fever (> 37.5 degrees C), and leucocytosis (> 10,000/ml) with or without purulent drainage. Five patients (38%) had infections during the first implantation, whereas eight patients (62%) had infections after replacement of the pulse generator. Early infection was observed in four patients (31%) and late infection in nine (69%). Incidence of infection was higher in patients who underwent epicardial cardioverter-defibrillator implantation (12/207 patients, 5.8%) than in those who received nonthoracotomy lead systems (1/125 patients, 0.8%) (P < 0.05). Infections were caused by staphyloccocus in 10 patients, pseudomonas in two patients, and streptococcus in one patient. The whole device had to be removed in all patients. During a mean follow up of 39 (29) months seven patients died: six of congestive heart failure and one of myocardial reinfarction. CONCLUSIONS: Infection, one of the most serious complications after cardioverter-defibrillator implantation, is associated with increased morbidity and mortality. When infection occurs the system must be removed to avoid a fatal outcome.

Adolescent↗
PubMed1995

[Pelvic symptoms 6 months after implantation of an automatic cardioverter-defibrillator].

Very few complications after implantation of an automatic cardioverter defibrillator (ICD) have been observed. Most complications are caused by infections, electrode problems and inappropriate ICD shocks caused by supraventricular tachyarrythmia. We report on a 64-year-old patient who received an ICD after successful resuscitation due to ventricular fibrillation. Six months after ICD implant the patient suffered from abdominal pain. Abdominal X-ray and ultrasound revealed perforation of the ICD into the pelvis. After operative revision and implantation into a new pulse generator pouch, the patient was fine up to 7 months later. Then incarceration of an epigastric hernia was present without any signs that the defibrillator pouch was involved.

Abdominal Pain↗
PubMed1995

[Cardioverter-defibrillator implantation in the heart catheterization laboratory--observations with 105 patients].

Today, we are facing an exponential increase in implantation of cardioverter defibrillators (ICD). The intraoperative and follow-up results are reported in 105 patients (pts) with ventricular tachyarrythmias who underwent ICD implantation in the catheterization laboratory. Fifty-seven pts (54%) hat their first ICD implant (G 1), whereas 46 pts (44%) underwent pulse generator replacement or electrode revision (2 pts, 2%) (G 2). In all pts, ICD implant or pulse generator replacement was performed under general anesthesia from the beginning. In 57/58 pts (98%) in G 1, ICD implantation was possible with a mean defibrillation threshold (DFT) of 13 +/- 8 joules. One patient hat a DFT of > 25 joules and ICD implantation was not achieved. This patient underwent epicardial lead implantation 1 day later. One patient in G 1 had a vessel rupture (v. subclavia) intraoperatively. During a mean follow-up of 5 +/- 2 (< 1-13) months, three pts (3%) died from congestive heart failure, 2, 4 and 6 months after device implantation. An infection occurred in 1 patient in G 2, 3 months after generator replacement. Our data show that in the majority of patients ICD implantation in the cath-lab is possible, safe, and the complication rate is low. Therefore, ICD implantation in the cath-lab can generally be recommended.

Adolescent↗
PubMed1995

[10 years of therapy with implantable defibrillators--observation in 353 patients].

Since January 1984, the cardioverter-defibrillator (ICD) has been implanted in 353 patients (pts). Epicardial ICD implantation was performed in 207 pts and 146 pts underwent non-thoracotomy ICD implant. Overall operative mortality was 3% (12/353 pts) and was significantly higher in pts with epicardial ICD implantation (11/207 pts, 5%) than in patients who received non-thoracotomy ICDs (1/146 pts, < 1%) (p < 0.05). During a mean follow-up of 25 +/- 23 months, 63 pts (19%) died: 8 pts (0.8% per year) from sudden arrhythmic death and 6 pts (0.8% per year) suddenly without an underlying arrhythmia. Cardiac death was observed in 36 pts (4% per year) and 13 pts (2% per year) died from other causes. Appropriate ICD discharges were observed in 245 pts (72%) with a mean incidence of 22 +/- 44 IC discharges per pt. In pts with third-generation ICDs, 3,542 ventricular tachyarrhythmias (VTA) were observed and terminated by primary ICD shocks in 778 VTA (22%). Antitachycardia pacing was attempted in 2,764 VTA (78%) and was successful in 2,484 VTA (90%).

Aged↗
PubMed1995

[Experiences with the new cardioverter-defibrillator Ventak PRxII].

Clinical safety and efficacy of the new third-generation implantable cardioverter defibrillator (ICD) Ventak PRxII was studied in 50 patients (pts) with ventricular tachycardia (VT) and/or fibrillation (VF). In 23 pts (46%) the ICD was implanted with a transvenous lead system as first implant and 27 pts (54%) received the Ventak PRxII as generator replacement. Intraoperatively, the mean defibrillation threshold (DFT) was 13 +/- 8 joules and 12 +/- 8 joules, respectively. One pt died perioperatively. During a follow-up of 5.3 +/- 3.8 months 3 patients died due to heart failure. During follow-up 1060 arrhythmia episodes (AE) occurred and were terminated primarily by countershock in 121 AE (11%). Antitachycardia pacing (ATP) was tried in 939 AE (89%) and was successful in 878 AE (94%). Acceleration was present in 6 AE (< 1%). We conclude that there is a high efficacy rate in AE termination by the Ventak PRxII, using ATP or countershock. Therefore, the Ventak PRxII allows a flexible approach to cardiac rhythm management.

Adult↗
PubMed1995

[The role of anti-tachycardia stimulation in patients with 3rd-generation defibrillators].

The most effective antitachycardia pacing mode (ATP) is still a matter of debate. Randomized prospective testing of 5 different ATP modes was performed in 82 patients (pts) prior to and after cardioverter defibrillator (ICD) implantation. The 5 ATP modes included 3-4 stimulation attempts with 4-10 adaptive scanning burst pulses. Adaptive burst coupling interval was 75% in mode A, 81% in mode B, 69% in mode C, 72% in mode D, and 88% in mode E. Auto-decremental scanning within bursts was 8 ms in modi A, B, and C, and 10 ms in modus E; autodecremental scanning between bursts was 8 ms in modi B and C, and 10 ms in modus D. During the pre-op electrophysiologic study (EP), termination (TR) of induced ventricular tachycardia (VT) was possible in 69% and by pre-discharge EP in 53%. Acceleration (AC) rates were 16% pre-op and 32% post-op (p = ns). There were no significant differences in TR or AC between modes A-E. During a mean follow-up of 18 +/- 4 (< 1-41) months, 3182 arrhythmia episodes (AE) occurred: 344 AE (11%) were terminated by primary ICD shocks and ATP was attempted in 2838 AE (89%) and was successful in 2576 AE (91%). AC occurred in 87 AE (3%) and ATP was without effect in 175 AE (6%). Our data show that ATP is helpful in patients with third-generation ICDs and is very effective during follow-up. However, there is no ideal ATP-mode visible in the present study.

Aged↗
PubMed1994

Nonpharmacological therapy of ventricular tachyarrhythmias: observations in 554 patients.

It has been shown that conventional antiarrhythmic drug treatment is debatable, and there is growing interest in nonpharmacological techniques. We studied the outcome of 554 patients with ventricular tachycardia (VT) or ventricular fibrillation (VF) who underwent nonpharmacological techniques from March 1980 to June 1994 at our institution. Catheter ablation was performed in 51 patients (G1), map guided surgery in 147 (G2), and cardioverter defibrillator implantation (ICD) in 356 (G3). During a mean follow-up of 37 +/- 12 (< 1-137) months, incidence of sudden death (G1 4%, G2 6%, G3 3%) and cardiac death (G1 7%, G2 16%, G3 8%) were relatively low, and there was no significant differences between G1-G3. VT/VF recurrences occurred more frequently in G1 (57%) than in G2 (18%) (P < 0.01). ICD discharges occurred in 69% of patients. We conclude that nonpharmacological techniques lead to low sudden death rates; however, there is a high rate of recurrence in G1. Risk stratification is necessary to select the ideal therapy for each individual patient.

Catheter Ablation↗
PubMed1994

[Ablation of permanent left atrial ectopic tachycardia by high-frequency energy].

Catheter ablation of ectopic atrial tachycardia has been previously reported in a small number of patients in whom the ectopic focus was predominantly located in the right atrium. We report on a 53-year-old patient with atrial automatic tachycardia originating in the left atrium, in whom successful radiofrequency catheter ablation was performed via a transseptal puncture. The patient presented a permanent atrial tachycardia for several years, refractory to antiarrhythmic drug treatment and DC-cardioversion. Radiofrequency ablation terminated left ectopic atrial tachycardia and, therefore, should be attempted before resorting to open-heart surgical ablation.

Cardiac Pacing, Artificial↗
PubMed1989

[Cibenzoline: electrophysiologic effects of a new class I anti-arrhythmia agents in supraventricular tachycardia].

Cibenzoline, an imidazoline derivate, is a new class 1 antiarrhythmic agent. The electrophysiologic effects and antiarrhythmic properties of cibenzoline (100 mg i.v.) were evaluated in 22 patients with paroxysmal supraventricular tachycardia: 12x Wolff-Parkinson-White Syndrome, 9x AV nodal reentrant tachycardia, 1x atrial tachycardia. Cibenzoline shortened the sinus cycle length from 742 +/- 103 ms to 661 +/- 87 ms (p less than 0.001) and the sinus node recovery time from 1026 +/- 106 ms to 926 +/- 135 ms (p less than 0.001). The substance lengthened the AH interval from 93 +/- 19 ms to 112 +/- 24 ms (p less than 0.001) and the HV interval from 42 +/- 12 ms to 61 +/- 14 ms (p less than 0.001). The effective refractory periods of the atrium and right ventricle did not change significantly, but the effective refractory period of the AV node in antegrade (269 +/- 42 ms vs 278 +/- 46 ms; p less than 0.05) and retrograde direction (281 +/- 57 ms vs 413 +/- 124 ms; p less than 0.001) increased markedly. Cibenzoline prolonged the effective refractory period of the accessory pathway in retrograde direction from 263 +/- 41 ms to 428 +/- 101 ms (p less than 0.001). The effective refractory period of the antegrade accessory pathway did not change. During atrial stimulation inducibility of the reentrant tachycardia was suppressed in 14 of 22 patients and the inducibility of atrial fibrillation in 7 of 12 patients. The RR interval of the reentrant tachycardia was prolonged from 353 +/- 57 ms to 420 +/- 57 ms (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1988

[Supraventricular tachycardia: therapy with a variable antitachycardia stimulation program].

Modern, microprocessor-controlled antitachycardia pacemakers are available with extended detection and termination programs for the treatment of supraventricular tachycardias. Using the "InterTach 262-12" we examined a universal antitachycardia pacing mode in the chronic state. Based on the individual electrophysiologic parameters, a defined burst stimulation mode was used for the first intervention and, consecutively, a determined scanning mode. The InterTach device was implanted in 17 patients with a mean age of 50 +/- 15 years: 10 with AV-nodal reentrant tachycardia, 6 with Wolff-Parkinson-White syndrome, 1 with reentrant tachycardia with Mahaim fibers. The mean tachycardia rate was 178 +/- 23/min and the follow-up 10 +/- 4 months. Every 3 months the efficacy of the termination mode was tested by programmed stimulation in supine and upright body position or during physical activity. In these tests, a rate of 95-100% successful terminations was observed. In the chronic state, 26 persistent tachycardias in 11 patients were noted; 21 episodes could be referred to an insufficient tachycardia detection. Only four persistent tachycardias were due to ineffective antitachycardia pacing. The introduction of extended variable termination programs, including consecutive, flexible pacing modes, can be considered as a marked advancement in the antitachycardia pacemaker therapy for supraventricular tachycardias.

Adult↗